Table 1 Sociodemographic and clinical data of TRS and CMS patients, and healthy controls

Age (years)∗

40.65 (9.18)

40.61 (10.27)

40.02 (9.28)

0.063 ^a

Education (years)∗

8.58 (2.53)

9.43 (3.02)

9.83 (3.06)

1.783 ^a

BMI (kg/m²)∗

24.79 (3.80)

24.33 (3.60)

25.92 (3.07)

2.856 ^a

Smoking (n, %)

12 (38.7%)

29 (59.2%)

20 (37.7%)

5.551 ^b

Age of onset (years)∗

25.58 (7.73)

27.88 (8.76)

-

1.428 ^a

Duration of illness (years)◊

13 (10, 22)

10 (7, 15)

-

− 1.98 ^c

PANSS total score∗

74.03 (7.35)

47.55 (7.96)

-

222.819^a

P subscores∗

14.03 (5.60)

9.12 (2.22)

-

30.353 ^a

N subscores∗

35.06 (4.64)

25.55 (4.19)

-

89.962 ^a

G subscores∗

24.94 (3.75)

13.33 (4.76)

-

132.125^a

Equivalent dose of chlorpromazine (mg/d)◊

675 (615, 825)

500 (430, 565)

-

− 7.51 ^c

RBANS total score∗

55.87 (9.98)

59.98 (11.18)

91.02 (11.83)

136.918^a

Immediate∗ memory∗

47.39 (11.99)

52.24 (19.10)

86.85 (17.06)

75.428 ^a

Visuospatial/

constructional∗

66.32 (15.46)

72.06 (14.64)

91.47 (15.21)

34.272 ^a

Language∗

69.45 (12.80)

73.61 (14.41)

99.15 (10.29)

76.009 ^a

Attention∗

79.16 (12.45)

84.16 (14.13)

108.72 (14.02)

60.735 ^a

Delay memory∗

52.90 (15.02)

55.02 (17.04)

87.26 (16.28)

65.847 ^a

TNF-α (pg/ml)∗

5.84 (4.57)

6.07 (4.77)

3.86 (2.99)

4.289 ^a

MMP-2 (ng/mL)∗

31.67 (3.05)

30.93 (2.92)

29.55 (3.63)

4.682 ^a